JPH06296860A - Porous support and adsorption material - Google Patents
Porous support and adsorption materialInfo
- Publication number
- JPH06296860A JPH06296860A JP5114270A JP11427093A JPH06296860A JP H06296860 A JPH06296860 A JP H06296860A JP 5114270 A JP5114270 A JP 5114270A JP 11427093 A JP11427093 A JP 11427093A JP H06296860 A JPH06296860 A JP H06296860A
- Authority
- JP
- Japan
- Prior art keywords
- porous support
- less
- adsorbent
- volume
- surface area
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000001179 sorption measurement Methods 0.000 title abstract description 26
- 239000000463 material Substances 0.000 title abstract description 8
- 239000011148 porous material Substances 0.000 claims abstract description 92
- 239000007787 solid Substances 0.000 claims abstract description 45
- 239000003446 ligand Substances 0.000 claims abstract description 27
- 239000003463 adsorbent Substances 0.000 claims description 42
- 239000000835 fiber Substances 0.000 claims description 35
- 239000012528 membrane Substances 0.000 claims description 18
- 239000002861 polymer material Substances 0.000 claims description 10
- 229920000620 organic polymer Polymers 0.000 claims description 4
- 239000000126 substance Substances 0.000 abstract description 20
- 238000000034 method Methods 0.000 description 34
- -1 polybutylene terephthalate Polymers 0.000 description 23
- 239000004698 Polyethylene Substances 0.000 description 15
- 229920000573 polyethylene Polymers 0.000 description 15
- 239000008280 blood Substances 0.000 description 12
- 210000004369 blood Anatomy 0.000 description 11
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 11
- 229910052753 mercury Inorganic materials 0.000 description 11
- 238000009987 spinning Methods 0.000 description 11
- 238000004804 winding Methods 0.000 description 11
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 10
- 238000009826 distribution Methods 0.000 description 8
- 210000001124 body fluid Anatomy 0.000 description 7
- 239000010839 body fluid Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 238000002074 melt spinning Methods 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 239000007789 gas Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000013076 target substance Substances 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 239000004593 Epoxy Substances 0.000 description 3
- 239000004721 Polyphenylene oxide Substances 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 108010071690 Prealbumin Proteins 0.000 description 3
- 102000007584 Prealbumin Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 125000003700 epoxy group Chemical group 0.000 description 3
- 239000004088 foaming agent Substances 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 229920001903 high density polyethylene Polymers 0.000 description 3
- 239000004700 high-density polyethylene Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 238000002459 porosimetry Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010894 electron beam technology Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 description 2
- 239000012510 hollow fiber Substances 0.000 description 2
- 210000001724 microfibril Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 229920002492 poly(sulfone) Polymers 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000005245 sintering Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 239000002759 woven fabric Substances 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- CHRJZRDFSQHIFI-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;styrene Chemical compound C=CC1=CC=CC=C1.C=CC1=CC=CC=C1C=C CHRJZRDFSQHIFI-UHFFFAOYSA-N 0.000 description 1
- CXCHEKCRJQRVNG-UHFFFAOYSA-N 2,2,2-trifluoroethanesulfonyl chloride Chemical compound FC(F)(F)CS(Cl)(=O)=O CXCHEKCRJQRVNG-UHFFFAOYSA-N 0.000 description 1
- SJIXRGNQPBQWMK-UHFFFAOYSA-N 2-(diethylamino)ethyl 2-methylprop-2-enoate Chemical compound CCN(CC)CCOC(=O)C(C)=C SJIXRGNQPBQWMK-UHFFFAOYSA-N 0.000 description 1
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102400000269 Amyloid protein A Human genes 0.000 description 1
- 101710144835 Amyloid protein A Proteins 0.000 description 1
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 1
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 1
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 238000004438 BET method Methods 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004641 Diallyl-phthalate Substances 0.000 description 1
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical group CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 1
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000446313 Lamella Species 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229920002292 Nylon 6 Polymers 0.000 description 1
- 229920002302 Nylon 6,6 Polymers 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229930182556 Polyacetal Natural products 0.000 description 1
- 239000004962 Polyamide-imide Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 239000004734 Polyphenylene sulfide Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 229920001807 Urea-formaldehyde Polymers 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 102000034337 acetylcholine receptors Human genes 0.000 description 1
- 125000004018 acid anhydride group Chemical group 0.000 description 1
- 229920000122 acrylonitrile butadiene styrene Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001004 anti-acetylcholinic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003429 anti-cardiolipin effect Effects 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 230000003172 anti-dna Effects 0.000 description 1
- 230000001986 anti-endotoxic effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- QUDWYFHPNIMBFC-UHFFFAOYSA-N bis(prop-2-enyl) benzene-1,2-dicarboxylate Chemical compound C=CCOC(=O)C1=CC=CC=C1C(=O)OCC=C QUDWYFHPNIMBFC-UHFFFAOYSA-N 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000010622 cold drawing Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- JMANVNJQNLATNU-UHFFFAOYSA-N glycolonitrile Natural products N#CC#N JMANVNJQNLATNU-UHFFFAOYSA-N 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002312 polyamide-imide Polymers 0.000 description 1
- 229920001707 polybutylene terephthalate Polymers 0.000 description 1
- 229920005668 polycarbonate resin Polymers 0.000 description 1
- 239000004431 polycarbonate resin Substances 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920000306 polymethylpentene Polymers 0.000 description 1
- 239000011116 polymethylpentene Substances 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 229920006380 polyphenylene oxide Polymers 0.000 description 1
- 229920000069 polyphenylene sulfide Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 239000013464 silicone adhesive Substances 0.000 description 1
- 238000009751 slip forming Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical group CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】溶液、特に体液中の成分を吸着す
るために吸着材が用いられている。本発明は、この吸着
材に有用な中実繊維膜状の多孔質支持体に関する。BACKGROUND OF THE INVENTION Adsorbents are used to adsorb components in solutions, especially body fluids. The present invention relates to a solid fiber membrane-like porous support useful for this adsorbent.
【0002】[0002]
【従来の技術】溶液中に溶解した物質を吸着するため
に、該物質と親和性のある分子を、多孔質の支持体表面
に不溶化した吸着材が、医療、工業等の分野や、分析な
どの基礎研究の分野で広く利用されている。この多孔質
支持体には、セルロースやデキストラン、キトサン、ス
チレン・ジビニルベンゼンなどの素材からなる球状ある
いはビーズ状の多孔質支持体が多く利用されている。特
に医学の分野では、病因物質等の疾患関連物質と選択的
に結合する分子、即ちリガンドを多孔質の支持体表面に
不溶化してなる吸着材を用いて、体外に取り出した患者
の血液或いは血漿等の体液を吸着材と接触させ、血液中
の疾患関連物質を吸着除去した後再度患者に戻す治療
法、例えば体外循環治療等で利用されている。例えば、
セルロース製のビーズ状多孔質支持体にデキストラン硫
酸を共有結合したもの、ポリビニルアルコール製のビー
ズ状多孔質支持体にトリプトファンを共有結合したもの
等である。2. Description of the Related Art In order to adsorb a substance dissolved in a solution, an adsorbent in which a molecule having an affinity for the substance is insolubilized on the surface of a porous support is used in the fields of medicine, industry, analysis, etc. Widely used in the field of basic research. As the porous support, a spherical or bead-shaped porous support made of a material such as cellulose, dextran, chitosan, or styrene / divinylbenzene is often used. Particularly in the field of medicine, a molecule that selectively binds to a disease-related substance such as a pathogen, that is, an adsorbent obtained by insolubilizing a ligand on the surface of a porous support is used to remove blood or plasma of a patient taken out of the body. It is used in a treatment method such as extracorporeal circulation treatment in which a body fluid such as the above is brought into contact with an adsorbent to adsorb and remove a disease-related substance in blood and then returned to the patient. For example,
Examples thereof include those in which dextran sulfate is covalently bonded to a bead-shaped porous support made of cellulose, and those in which tryptophan is covalently bonded to a bead-shaped porous support made of polyvinyl alcohol.
【0003】これらビーズ状の多孔質支持体は細密充填
が難しく、プライミングボリュームが大きいなどの問題
点があった。この問題点を解決する目的で、繊維状の多
孔質吸着材が知られている(特開昭60−24676
5)。該発明に示された繊維状の多孔質吸着材は、上記
ビーズ状支持体を用いた吸着材の問題点を解決したもの
であったが、本発明者らの研究によると支持体としての
機能が不十分であり、吸着材として満足に用いられるも
のではなかった。吸着材単位容積当たりの被吸着物質の
吸着量、即ち吸着性能は多孔質支持体が被吸着物質の接
触・吸着可能な表面積を如何に多く有しているかによっ
て決まる。該表面積は吸着材担体の外部表面積と内部表
面積の和であるが、従来ビーズ状担体では内部表面積を
大きくする目的で孔径を大きくする、或いは孔数を増や
すなどが成されているが、ビーズ状担体で得られる孔は
本発明とは異なり実質的には貫通せず、表面から内部に
いくにつれ小さくなるので孔内に吸着した被吸着物質に
よって封鎖され、それ以上の被吸着物質を含む体液は流
入できない或いは、内部に入り込む被吸着物質を含む体
液は拡散によるもので限度がある、等の問題点があっ
た。また、外部表面積を大きくする目的でビーズ状担体
の粒子径を小さくすると通液抵抗が大となり、さらには
粒子がカラム外へ流出する恐れもあり危険である。つま
り有効に使うことができる表面積の増大には限度があっ
た。These bead-shaped porous supports have problems that it is difficult to densely pack them and the priming volume is large. For the purpose of solving this problem, a fibrous porous adsorbent is known (JP-A-60-24676).
5). The fibrous porous adsorbent shown in the invention has solved the problem of the adsorbent using the above bead-shaped support, but according to the studies by the present inventors, it functions as a support. Was insufficient and was not satisfactorily used as an adsorbent. The adsorption amount of the adsorbed substance per unit volume of the adsorbent, that is, the adsorption performance is determined by how much surface area of the porous support the contactable / adsorbable of the adsorbed substance is. The surface area is the sum of the external surface area and the internal surface area of the adsorbent carrier. In the conventional bead-shaped carrier, the pore diameter is increased or the number of pores is increased in order to increase the internal surface area. Unlike the present invention, the pores obtained by the carrier do not substantially penetrate, and become smaller from the surface to the inside, so that they are blocked by the adsorbed substance adsorbed in the pores, and body fluid containing more adsorbed substances is There is a problem that the body fluid containing the substance to be adsorbed that cannot flow in or enters the inside is limited due to diffusion. Further, if the particle diameter of the bead-shaped carrier is reduced for the purpose of increasing the external surface area, the liquid resistance becomes large, and further, the particles may flow out of the column, which is dangerous. In other words, there is a limit to the increase in surface area that can be effectively used.
【0004】[0004]
【発明が解決しようとする課題】そこで特開昭60−2
46765の繊維状の多孔質吸着材よりも更に優れた中
実繊維膜状の吸着材を得るべく、特に吸着材の多孔質支
持体について鋭意研究した結果本発明を成すに至った。
本発明者らの研究によると特開昭60−246765の
繊維状の多孔質体に均一な貫通孔をもつ中実繊維膜を使
うと孔内へも被吸着物質を含む体液は自由に出入りし内
部孔面積を有効に活用でき、同時に通液抵抗もなく操作
出来るという事を見出した。また、中実繊維膜はリガン
ドを付けるにも適した材料である。即ち、本発明の目的
は、リガンドの付着が容易で、かつ吸着能力が優れた吸
着材用の多孔質支持体を提供するにある。DISCLOSURE OF THE INVENTION Problem to be Solved by the Invention
In order to obtain an adsorbent in the form of a solid fiber membrane, which is even better than the fibrous porous adsorbent of 46765, the present invention has been accomplished as a result of earnest research on the porous support of the adsorbent.
According to the research conducted by the present inventors, when a solid fibrous membrane having uniform through holes is used in the fibrous porous body of JP-A-60-246765, the body fluid containing the substance to be adsorbed also freely enters and leaves the pores. It was found that the internal hole area can be effectively used and at the same time, it can be operated without resistance to liquid passage. Further, the solid fiber membrane is a material suitable for attaching a ligand. That is, an object of the present invention is to provide a porous support for an adsorbent, which is easy to attach a ligand and has excellent adsorption ability.
【0005】本発明の要旨は下記のとおりのものであ
る。平均孔径が0.01μm以上10μm以下の細孔を
有し、全表面積3m2 /g以上500m2 /g以下、孔
径0.01μm以上10μm以下の細孔の容積が全細孔
容積の40%以上を有する有機高分子材料からなる中実
繊維膜状多孔質支持体。平均孔径が0.01μm以上1
0μm以下の細孔を有し、全表面積3m2 /g以上50
0m2 /g以下、孔径0.01μm以上10μm以下の
細孔の容積が全細孔容積の40%以上を有する有機高分
子材料からなる中実繊維膜状多孔質支持体の表面上に、
リガンドを不溶化してなる吸着材。以下に、本発明を項
目別に説明する。The gist of the present invention is as follows. Pore having an average pore size of 0.01 μm or more and 10 μm or less, a total surface area of 3 m 2 / g or more and 500 m 2 / g or less, and a volume of pores having a pore size of 0.01 μm or more and 10 μm or less is 40% or more of the total pore volume. A solid fiber membrane-like porous support made of an organic polymer material having Average pore size is 0.01 μm or more 1
Pore size of 0 μm or less and total surface area of 3 m 2 / g or more 50
On the surface of a solid fiber membrane-like porous support made of an organic polymer material having a pore volume of 0 m 2 / g or less and a pore diameter of 0.01 μm or more and 10 μm or less of 40% or more of the total pore volume,
An adsorbent made by insolubilizing a ligand. The present invention will be described below item by item.
【0006】内部表面積の定義 多孔質担体内の全孔の表面積の総和を言う。Definition of internal surface area: The total surface area of all pores in a porous carrier.
【0007】孔径 中実繊維膜状多孔質支持体の細孔径と細孔容積は水銀圧
入法により水銀圧曲線から得られる。ここで言う細孔
は、できるだけ実用時に近い状態での値であることが良
く、吸着材としての使用形態時の値をいう。又、水銀圧
入法での測定時の乾燥処理によって形状が変わる場合
は、中実繊維膜状多孔質支持体径の変化を測定し、表面
積は中実繊維膜状多孔質支持体径の変化率の2乗、細孔
容積は中実繊維膜状多孔質支持体径の3乗倍して補正す
ることとした。即ち中実繊維膜状多孔質支持体径が1/
X倍となった時、表面積は1/X2 倍、細孔容積は1/
X3 倍となったとする。中実繊維膜状多孔質支持体の平
均孔径は、細孔を円筒形であると仮定して全細孔体積を
細孔全表面積によって割り算することによって求められ
る。この平均孔径は、0.01μm未満では被吸着物質
が中実繊維膜状多孔質支持体の内部にまで十分に侵入せ
ず、十分な吸着能力が得られず、又10μmを超える
と、強度が下がって変形し易くなる危険性が増加し、
又、全表面積が小さくなりやはり十分な吸着能力は得ら
れず、実用上好ましくない。好ましい平均孔径は0.0
1μm以上で且つ10μm以下である。0.05μm以
上であることがより好ましく、特に0.1μm以上であ
ることが最も好ましい。更に2μm以下であることがよ
り好ましく、特に1μm以下であることが最も好まし
い。Pore size The pore size and pore volume of the solid fibrous membrane-like porous support can be obtained from the mercury pressure curve by the mercury intrusion method. It is preferable that the pores referred to here have a value in a state as close to practical use as possible, and a value when used as an adsorbent. Also, if the shape changes due to the drying process during measurement with the mercury porosimetry, the change in the diameter of the solid fiber membrane porous support is measured, and the surface area is the rate of change in the diameter of the solid fiber membrane porous support. , And the pore volume is corrected by multiplying the diameter of the solid fibrous membrane-like porous support by the cube of the diameter. That is, the diameter of the solid fiber membrane porous support is 1 /
When it becomes X times, the surface area is 1 / X 2 times and the pore volume is 1 /
Suppose that the number has increased by 3 times. The average pore size of the solid fibrous membranous porous support is determined by dividing the total pore volume by the total pore surface area, assuming that the pores are cylindrical. When the average pore diameter is less than 0.01 μm, the substance to be adsorbed does not sufficiently penetrate into the inside of the solid fibrous membrane-like porous support, and sufficient adsorption ability cannot be obtained. The risk of lowering and deforming increases,
In addition, the total surface area becomes small and sufficient adsorption capacity cannot be obtained, which is not preferable in practice. The preferred average pore size is 0.0
It is 1 μm or more and 10 μm or less. It is more preferably at least 0.05 μm, and most preferably at least 0.1 μm. It is more preferably 2 μm or less, and most preferably 1 μm or less.
【0008】孔形状 細孔は円形、楕円形、短冊形、星形、多角形、不定形、
その他いずれの形状であっても良いが、円形、楕円形、
短冊形であることが、支持体内部への被吸着物質の進入
のしやすさの点でより好ましい。この中で特に短冊形が
最も好ましい。更に、いずれの細孔形状であっても貫通
孔であることが、リガンドを支持体内部にまで均一に不
溶化でき、しかも被吸着物質が吸着材内部にまで容易に
進入できるため、非常に好ましい。Pore shape The pores are circular, elliptical, strip-shaped, star-shaped, polygonal, amorphous,
It may have any other shape, but it may be circular, oval,
The strip shape is more preferable in terms of the ease with which the substance to be adsorbed enters the support. Of these, the strip shape is most preferable. Further, it is highly preferable that the pores are through-holes regardless of the shape of the pores, because the ligand can be uniformly insolubilized even inside the support, and the substance to be adsorbed can easily enter the inside of the adsorbent.
【0009】孔径分布 孔径は、本発明の中実繊維膜状多孔質支持体では繊維表
面から中心部までより均質な孔を得られて、内部まで有
効に吸着に利用し易いため、ビーズ状多孔質支持体と異
なりブロードな孔径分布にして内部まで有効に利用しよ
うとする試みは特に重要でない。中実繊維膜状多孔質支
持体ではシャープな孔径分布にすることが、有効表面積
を吸着材単位容積当たりより多く確保できるためより好
ましい。このため0.01μm以上10μm以下の孔径
の容積が全細孔容積の40%以上であることが好まし
く、70%以上の時より好ましい。更には0.05μm
以上5μm以下の孔径の容積が全容積の40%以上であ
ることがより好ましい。70%以上の時更に好ましく、
特に80%という非常にシャープな分布であることが最
も好ましい。Pore size distribution In the solid fiber membrane-like porous support of the present invention, more uniform pores can be obtained from the fiber surface to the central portion, and it is easy to effectively utilize the inside to be adsorbed. Unlike the quality support, an attempt to make a broad pore size distribution and effectively utilize the inside is not particularly important. In the case of a solid fibrous film-like porous support, it is more preferable to have a sharp pore size distribution because a larger effective surface area can be secured per unit volume of the adsorbent. Therefore, the volume of pores having a diameter of 0.01 μm or more and 10 μm or less is preferably 40% or more of the total pore volume, and more preferably 70% or more. Furthermore, 0.05 μm
More preferably, the volume of pores having a diameter of 5 μm or less is 40% or more of the total volume. More preferable when 70% or more,
It is most preferable that the distribution is very sharp, especially 80%.
【0010】全表面積 本発明の中実繊維膜状多孔質支持体の乾燥重量に対する
全表面積は、特に1m2 /g以上であることが好まし
く、より好ましくは5m2 /g以上であり、更に好まし
くは10m2 /g以上である。全表面積は大きければ大
きいほど吸着能力は高くなるのは自明であるが、体外循
環治療用の吸着材の多孔質支持体とし用いる場合は、全
表面積が大きくなり過ぎると吸着目的物質以外の物質の
非特異吸着も又増加する危険性が高くなる。特に血液や
体液に対して使用する場合は共存する有用な微量蛋白質
も多く、これらの非特異吸着量が増加することは好まし
くない。よって500m2 /g以下であることが好まし
く、より好ましくは300m2 /g以下であり、最も好
ましくは150m2 /g以下である。Total Surface Area The total surface area, based on dry weight, of the solid fiber membrane-like porous support of the present invention is particularly preferably 1 m 2 / g or more, more preferably 5 m 2 / g or more, further preferably Is 10 m 2 / g or more. Obviously, the larger the total surface area, the higher the adsorption capacity, but when used as a porous support for an adsorbent for extracorporeal circulation treatment, if the total surface area becomes too large, substances other than the adsorption target substance The risk of non-specific adsorption also increases. Particularly when used for blood or body fluid, many useful trace proteins coexist, and it is not preferable that the nonspecific adsorption amount of these proteins increases. Therefore, it is preferably 500 m 2 / g or less, more preferably 300 m 2 / g or less, and most preferably 150 m 2 / g or less.
【0011】孔径、孔径分布、表面積の測定方法 細孔径及び細孔分布は水銀圧入法により、水銀圧入曲線
によって求めることが出来る。また表面積は窒素などの
ガスを用いて、その吸着量より求める事も出来るが、
(BET法)細孔分布と対比した表面積が得られるた
め、細孔径と同様に水銀圧入法によって求める事が好ま
しい。具体的な孔径、孔径分布、表面積の測定は、水銀
ポロシメーター(島津製作所製、マイクロメリティック
ス・ポアサイズ9320)を用いて測定できる。測定結
果はポアプロットシステム(島津製作所社製、9320
−PC2(V1.0))にて分析し、孔径、孔径分布、
表面積を求めることが出来る。この時水銀の圧力範囲は
1〜30,000psiaとした。Method of Measuring Pore Size, Pore Size Distribution, Surface Area The pore size and pore size can be determined by mercury intrusion curve and mercury intrusion curve. The surface area can also be calculated from the amount of adsorption using a gas such as nitrogen,
(BET method) Since the surface area can be obtained in comparison with the pore size distribution, it is preferable to determine it by the mercury intrusion method like the pore size. The specific pore diameter, pore diameter distribution, and surface area can be measured using a mercury porosimeter (manufactured by Shimadzu Corporation, Micromeritics Pore Size 9320). Pore Plot System (Shimadzu Corporation, 9320)
-PC2 (V1.0)) to analyze the pore size, pore size distribution,
The surface area can be determined. At this time, the pressure range of mercury was 1 to 30,000 psia.
【0012】細孔容積 中実繊維膜状多孔質支持体の全細孔容積は、中実繊維膜
状多孔質支持体の乾燥重量あたりの細孔容積の総量で示
すと、0.1ml/g以上で且つ50ml/g以下であ
ることが好ましい。全細孔容積が0.1ml/g未満で
は、実用上有効に働く表面積が少なくなってしまうため
十分な吸着能力が得られない。又全細孔容積が50ml
/gを超えると中実繊維膜状多孔質支持体の強度が低く
なり、使用上好ましくない。更に中実繊維膜状多孔質支
持体の全細孔容積のより好ましい範囲を示すと、0.5
ml/g以上30ml/g以下であり、より好ましくは
1ml/g以上10ml/g以下である。Pore Volume The total pore volume of the solid fiber membrane-like porous support is 0.1 ml / g when expressed as the total amount of the pore volume per dry weight of the solid fiber membrane-like porous support. It is preferably not less than 50 ml / g. If the total pore volume is less than 0.1 ml / g, the surface area that works effectively in practice will be small, and sufficient adsorption capacity cannot be obtained. The total pore volume is 50 ml
If it exceeds / g, the strength of the solid fiber membrane-like porous support becomes low, which is not preferable in use. A more preferable range of the total pore volume of the solid fiber membrane-like porous support is 0.5
ml / g or more and 30 ml / g or less, more preferably 1 ml / g or more and 10 ml / g or less.
【0013】中実繊維膜状多孔質支持体の定義 本発明でいう中実繊維膜状多孔質支持体とは、目的とす
る物質と親和性のある分子、即ちリガンドを表面に不溶
化することによって吸着材とするための、表面に開孔し
た多くの細孔を有する多孔質支持体であって、太さに対
して長手方向の長さが十分に長い、糸状或いは繊維状の
ものをいい、断面の形状が円、楕円、多角形状、星形等
いずれの形状であっても良い。更に断面中央部に、長手
方向に沿って実質的に同一形状で貫通した孔を有さな
い。ここで言う断面中央部に、長手方向に沿って実質的
に同一形状で貫通した孔とは、中空糸膜が有する、例え
ば紡糸時に連続的に形成される、中空糸外部と膜で隔て
られた内部空間等を指し、細孔の連続によって不規則に
形成されたものをいわない。Definition of solid fiber membrane-like porous support The solid fiber membrane-like porous support in the present invention means that a molecule having an affinity for a target substance, that is, a ligand is insolubilized on the surface. For the adsorbent, a porous support having a large number of pores opened on the surface, which has a sufficiently long length in the longitudinal direction with respect to the thickness, a filamentous or fibrous material, The shape of the cross section may be any shape such as a circle, an ellipse, a polygon, and a star. Furthermore, the central portion of the cross section does not have a hole penetrating in a substantially same shape along the longitudinal direction. The hole penetrating in the central part of the cross section along the longitudinal direction with substantially the same shape is separated by the membrane from the outside of the hollow fiber, which the hollow fiber membrane has, for example, is continuously formed during spinning. Refers to the internal space, etc., and does not refer to those formed irregularly by the continuity of pores.
【0014】中実繊維膜状多孔質支持体の長さ、太さ 中実繊維膜状多孔質支持体の長手方向の長さは、太さ、
即ち径に対して実質的に長ければ良く特に規定は不要で
あるが、取扱い性の点で50mm以上であることが好ま
しい。径は、細過ぎると中実繊維膜状多孔質支持体が切
れ易く取扱い性が悪くなり、太過ぎるとおそらく被吸着
物質が中実繊維膜状多孔質支持体内部に浸入しにくくな
るために吸着能力が低くなってしまうため、断面積を円
に換算した時の直径で1μm以上10mm以下が好まし
く、10μm以上1mm以下が更に好ましい。特により
好ましくは50μm以上300μm以下である。Length and Thickness of Solid Fiber Membrane Porous Support The length of the solid fiber membrane porous support in the longitudinal direction is
That is, it suffices that the diameter is substantially longer than the diameter, and no particular regulation is required, but in terms of handleability, it is preferably 50 mm or more. If the diameter is too thin, the solid fibrous membrane-like porous support will be easily cut, resulting in poor handleability.If it is too thick, the substance to be adsorbed will probably be difficult to penetrate into the solid fibrous membrane-like porous support, so adsorption Since the ability becomes low, the diameter when the cross-sectional area is converted into a circle is preferably 1 μm or more and 10 mm or less, more preferably 10 μm or more and 1 mm or less. Particularly preferably, it is 50 μm or more and 300 μm or less.
【0015】材料 中実繊維膜状多孔質支持体には、支持体自体の安定性に
優れ、溶出物がなく、乾燥・湿潤状態間の形状変化も少
なく、支持体表面へのリガンド固定が容易且つ効率良く
行なえるため、有機合成高分子材料であることが好まし
い。具体的材料としてはナイロン6、ナイロン66など
のナイロン樹脂、ポリアセタール樹脂、ポリカーボネー
ト樹脂、変性ポリフェニレンオキシド樹脂、ポリブチレ
ンテレフタレート、ポリエチレンテレフタレート、ポリ
フェニレンスルファイド、ジアリルフタレート、ポリイ
ミド、ポリアミドイミド、ポリメチルペンテン、ポリス
ルフォン、ポリエーテルフルフォン、ポリアクリレー
ト、ポリエーテルエステルケトン、ポリテトラフルオロ
エチレン、ポリエチレン、ポリプロピレン、ポリ塩化ビ
ニル、ポリスチレン、フェノール、エポキシ、ポリウレ
タン、ポリビニルアセタール、ビスコール、ABS、エ
チレンビニルアルコール、ゴムユリア樹脂、セルロー
ス、セルロースアセテート、ポリメチルメタアクリレー
ト等のいずれか或いはこれらを含む共重合体が挙げら
れ、特にリガンドの不溶化や滅菌操作時の安定性の点よ
り合成高分子材料である事が好ましい。これらの中で中
実繊維膜状への成型のしやすさや好ましい細孔の形成が
容易であること、更には柔軟性の点より、ポリエチレ
ン、ポリプロピレン等のポリオレフィン、ポリスルフォ
ン、ポリメチルメタアクレリート、セルロースを成分と
して含む高分子材料がより好ましく、特にポリエチレ
ン、ポリプロピレン等のポリオレフィン系の高分子材料
が、短冊状の貫通孔が得られ最も好ましい。Material The solid fibrous membrane porous support has excellent stability of the support itself, no eluate, little change in shape between dry and wet states, and easy ligand immobilization on the surface of the support. In addition, an organic synthetic polymer material is preferable because it can be efficiently performed. Specific materials include nylon resin such as nylon 6 and nylon 66, polyacetal resin, polycarbonate resin, modified polyphenylene oxide resin, polybutylene terephthalate, polyethylene terephthalate, polyphenylene sulfide, diallyl phthalate, polyimide, polyamideimide, polymethylpentene, poly Sulfone, polyether fluphone, polyacrylate, polyether ester ketone, polytetrafluoroethylene, polyethylene, polypropylene, polyvinyl chloride, polystyrene, phenol, epoxy, polyurethane, polyvinyl acetal, biscol, ABS, ethylene vinyl alcohol, rubber urea resin, Cellulose, cellulose acetate, polymethylmethacrylate, etc. or this Copolymers can be mentioned including, it is particularly preferably a synthetic polymer material from the point of view of stability during insolubilization and sterilization operations of the ligand. Among them, polyolefins such as polyethylene and polypropylene, polysulfone, and polymethylmetaacrylate are easy to form into a solid fiber membrane and easy to form preferable pores, and also from the viewpoint of flexibility. Further, a polymer material containing cellulose as a component is more preferable, and a polyolefin polymer material such as polyethylene or polypropylene is particularly preferable because a strip-shaped through hole can be obtained.
【0016】製造方法1 中実繊維膜状多孔質支持体の製造には、特有の温度で分
解して窒素ガス、炭酸ガス等を生じる有機、或いは無機
の発泡剤を用いる発泡剤分解法、蒸発型溶剤を原料段階
で添加混合し、合成時に溶剤を気散発泡させる溶剤気散
法、常態でガス状の発泡剤を機械的に混合気泡させる気
体混入法、重合過程で発生するガスを利用する化学反応
法、可溶性物質を高分子材料中に分散させた後に溶出す
る溶出法、粉末を溶融温度以下の燒結作用で粒子を互い
に結合させる燒結法、湿式相転換法、溶融相分離法、溶
融紡糸延伸開孔法などを用いることができる。この中で
好ましい繊維径の支持体が得やすいことより、湿式相転
換法、溶融相分離法、溶融紡糸延伸開孔法が好ましく、
特に繊維状の形状を容易に得られること、高分子材料に
溶剤その他の添加物を用いないため残留溶剤などの問題
がないことより、結晶性高分子を溶融紡糸して繊維状に
成形した後、冷延伸により結晶ラメラ間を開裂させ、更
に熱延伸により孔径を拡大させて得られるスタックドラ
メラとミクロフィブリルとからなる多孔質構造を形成さ
せる延伸開孔法が特に好ましい。細孔がスタックドラメ
ラとミクロフィブリルとからなる多孔質構造の時、多孔
質構造内への溶液の流れ抵抗が少なく、よって繊維状多
孔質支持体内部へのリガンド固定が内部まで均質に行
え、吸着材として内部まで有効に使用できるため特に好
ましい。Production Method 1 The production of the solid fibrous membrane-like porous support is carried out by a foaming agent decomposition method using an organic or inorganic foaming agent which decomposes at a specific temperature to generate nitrogen gas, carbon dioxide gas or the like, and evaporation. Mold solvent is added and mixed at the raw material stage, and the solvent vaporization method is used to vaporize and foam the solvent during synthesis, the gas mixing method is used to mechanically mix and foam the gaseous foaming agent in the normal state, and the gas generated in the polymerization process is used. Chemical reaction method, elution method in which soluble substance is dispersed in polymer material and then eluted, sintering method in which powder particles are bonded to each other by a sintering action below melting temperature, wet phase conversion method, melt phase separation method, melt spinning A stretching opening method or the like can be used. Among them, the wet phase conversion method, the melt phase separation method, and the melt spinning draw opening method are preferable because a support having a preferable fiber diameter is easily obtained.
In particular, it is easy to obtain a fibrous shape, and since no solvent or other additives are used in the polymer material, there is no problem of residual solvent, so after melt-spinning the crystalline polymer into a fibrous shape. A stretch-opening method is particularly preferable in which the crystal lamellae are cleaved by cold stretching and the pore size is expanded by hot stretching to form a porous structure composed of a stacked lamella and microfibrils. When the pores have a porous structure composed of stacked lamellae and microfibrils, the flow resistance of the solution into the porous structure is small, so that the ligand can be fixed inside the fibrous porous support uniformly to the inside. It is particularly preferable because it can be effectively used as an adsorbent even inside.
【0017】製造方法2 本発明の多孔質支持体の製造例を、ポリエチレン材料を
例にとって示す。高密度ポリエチレン(密度0.6以
上、メルトインデックス値4以上7以下)を紡口径5m
m以上50mm以下の例えば円形の紡口を用いて、紡口
温度130℃以上200℃以下、ポリエチレン吐出量2
g/分以上30g/分以下、巻き取り速度50m/分以
上1,000m/分以下で溶融紡糸する。この時の巻き
取り時の張力は0.5gf以上50gf以下である。得
られたポリエチレン糸を80℃以下の温度で1.1倍以
上3.0倍以下に冷延伸し、次に100℃以上の温度で
1.2倍以上10倍以下に熱延伸して延伸開孔する事
で、中実繊維膜状多孔質構造のポリエチレン製の多孔質
支持体が得られる。総延伸倍率は1.5倍以上20倍以
下である。Production Method 2 A production example of the porous support of the present invention will be described by taking a polyethylene material as an example. High-density polyethylene (density 0.6 or more, melt index value 4 or more and 7 or less) spinning diameter 5 m
For example, using a circular spinneret of m or more and 50 mm or less, the spinneret temperature is 130 ° C. or more and 200 ° C. or less, and the polyethylene discharge amount is 2
Melt spinning is performed at g / min or more and 30 g / min or less and a winding speed of 50 m / min or more and 1,000 m / min or less. The tension at the time of winding at this time is 0.5 gf or more and 50 gf or less. The obtained polyethylene yarn is cold-stretched at a temperature of 80 ° C. or less to 1.1 times or more and 3.0 times or less, and then thermally stretched at a temperature of 100 ° C. or more to 1.2 times or more and 10 times or less and stretched. By forming pores, a polyethylene porous support having a solid fiber membrane-like porous structure can be obtained. The total draw ratio is 1.5 times or more and 20 times or less.
【0018】リガンドの種類 中実繊維膜状多孔質支持体は、その表面に吸着目的物質
との親和性を有する物質、即ちリガンドを不溶化して使
用できる。リガンドには吸着目的物質に対して親和性を
有する公知の合成物や、天然物質を使用できる。例えば
抗低密度リポ蛋白質抗体、トリプトファン、アセチルコ
リンレセプター由来ポリペプチド、フェニルアラニン、
シビレエイ由来ポリペプチド、血液型(A型、B型)抗
原、プロテインA、トリメチルアンモニウム基、ジメチ
ルアンモニウム基、アスパルテーム、ポリミキシンB、
抗免疫グロブリン抗体、抗CD8抗体や抗CD4抗体等
の抗白血球分化抗原抗体、抗癌壊死因子抗体等の抗サイ
トカイン抗体、抗エンドトキシン抗体、一本鎖或いは二
本鎖DNA等である。更にこれらの内、2種以上のリガ
ンドが不溶化されていても良い。これらのリガンドの分
子量はいずれの分子量のものであっても良いが、実用性
の点より1,000,000以下が利用しやすい。Kind of Ligand The solid fiber membrane-like porous support can be used by insolubilizing a substance having an affinity for the adsorption target substance, that is, a ligand, on its surface. As the ligand, a known synthetic compound having an affinity for the adsorption target substance or a natural substance can be used. For example, anti-low density lipoprotein antibody, tryptophan, acetylcholine receptor-derived polypeptide, phenylalanine,
Torpedo-derived polypeptide, blood group (A type, B type) antigen, protein A, trimethylammonium group, dimethylammonium group, aspartame, polymyxin B,
Anti-immunoglobulin antibody, anti-leukocyte differentiation antigen antibody such as anti-CD8 antibody and anti-CD4 antibody, anti-cytokine antibody such as anti-cancer necrosis factor antibody, anti-endotoxin antibody, single-stranded or double-stranded DNA and the like. Further, of these, two or more kinds of ligands may be insolubilized. The molecular weight of these ligands may be any molecular weight, but from the practical point of view, 1,000,000 or less is easily available.
【0019】リガンドの固定方法 リガンドを中実繊維膜状多孔質支持体に不溶化する方法
には、リガンドを溶解した液中に浸漬、或いは該液を噴
霧することによってコーティングする方法、化学的に或
いは放射線や電子線を用いてのグラフト法によって中実
繊維膜状多孔質支持体表面に共有結合する方法、或いは
化学的方法により中実繊維膜状多孔質支持体表面の官能
基を介して共有結合する方法などがある。この中でグラ
フト法、官能基を介しての共有結合法が使用時のリガン
ド溶出の危険性がなく、好ましい。中実繊維膜状多孔質
支持体に官能基を得る方法の1例としてはハロゲン化シ
アン法、エピクロルヒドリン法、エピブロムヒドリン
法、ビスエポキシド法、ブロモアセチルブロミド法、ト
レシルクロライド法、プロモアセトアミド法等が知られ
ている。具体的にはアミノ基、カルボキシル基、ヒドロ
キシル基、チオール基、酸無水物基、サクシニルイミド
基、塩素基、アルデヒド基、アミド基、エポキシ基、ト
レシル基などがあげられる。この中で加熱滅菌時の安定
性よりエピクロルヒドリン法やエピブロムヒドリン法で
誘導されるエポキシ基が特に好ましい例としてあげられ
る。Ligand Immobilization Method The ligand can be insolubilized in the solid fiber membrane-like porous support by dipping in a liquid in which the ligand is dissolved or by spraying the liquid, chemically or A method of covalently bonding to the surface of the solid fiber membrane porous support by a grafting method using radiation or electron beam, or a covalent bond via a functional group on the surface of the solid fiber membrane porous support by a chemical method. There are ways to do it. Among them, the grafting method and the covalent bonding method via a functional group are preferable because there is no risk of ligand elution during use. As an example of a method for obtaining a functional group on a solid fiber membrane-like porous support, a cyanogen halide method, an epichlorohydrin method, an epibromhydrin method, a bisepoxide method, a bromoacetyl bromide method, a tresyl chloride method, promoacetamide The law is known. Specific examples include an amino group, a carboxyl group, a hydroxyl group, a thiol group, an acid anhydride group, a succinylimide group, a chlorine group, an aldehyde group, an amide group, an epoxy group and a tresyl group. Among these, epoxy groups derived from the epichlorohydrin method and the epibromhydrin method are particularly preferable because of their stability during heat sterilization.
【0020】リガンドの固定量 導入するリガンドの量は特に規定は不要であるが、少な
すぎると吸着能力が低く、多過ぎると使用時にリガンド
が遊離する危険性が生じるため、中実繊維膜状多孔質支
持体の細孔容積を含む容積当たり1ng/ml以上10
0mg/ml以下であることが良い。更に、あえてより
好ましい範囲としては1μg/ml以上100μg/m
l以下があげられる。Fixed amount of ligand The amount of the ligand to be introduced is not particularly specified, but if it is too small, the adsorption capacity is low, and if it is too large, the ligand may be released during use. 1 ng / ml or more per volume including the pore volume of the quality support 10
It is preferably 0 mg / ml or less. Furthermore, the more preferable range is 1 μg / ml or more and 100 μg / m or more.
1 or less.
【0021】用途 中実繊維膜状多孔質支持体の用途としては水或いは有機
溶剤中の溶解物の吸着が有り、特に血液などの体液中の
蛋白質、糖、核酸、ホルモン、脂質、サイトカイン等の
吸着剤用支持体として適する。最も好ましくは、臨床に
おける体外循環治療用選択的或いは特異的吸着材の支持
体として使用できる。臨床における体外循環治療用選択
的或いは特異的吸着の用途としては、胆汁酸、アミロイ
ド前駆蛋白A、癌壊死因子、ビリルビン、ビリルビン結
合アルブミン、エンドトキシン、抗カルジオリピン抗
体、抗アセチルコリンレセプター抗体、低密度及び/ま
たは極低密度リポ蛋白質、スルファチド付着性蛋白質、
活性化補体成分、アミロイド蛋白A、免疫複合体、抗血
液型抗体、抗血小板抗体、抗DNA抗体やリウマチ因子
等の自己抗体及び/または該自己抗体を生産する免疫B
細胞、T細胞、免疫グロブリンL鎖、血液凝固第VII
I因子、血液凝固第IX因子、β2 ミクログロブリン等
があげられる。Uses The solid fibrous membrane-like porous support is used for adsorbing a dissolved substance in water or an organic solvent, and particularly for proteins, sugars, nucleic acids, hormones, lipids, cytokines and the like in body fluids such as blood. Suitable as a support for adsorbents. Most preferably, it can be used as a support for a selective or specific adsorbent for clinical extracorporeal circulation treatment. Clinically, the use of selective or specific adsorption for extracorporeal circulation treatment includes bile acid, amyloid precursor protein A, cancer necrosis factor, bilirubin, bilirubin-conjugated albumin, endotoxin, anti-cardiolipin antibody, anti-acetylcholine receptor antibody, low density and / or Or very low density lipoprotein, sulfatide adhesion protein,
Activated complement component, amyloid protein A, immune complex, anti-blood group antibody, anti-platelet antibody, auto-antibody such as anti-DNA antibody and rheumatoid factor, and / or immunity B producing the auto-antibody
Cells, T cells, immunoglobulin L chains, blood coagulation VII
Examples include factor I, blood coagulation factor IX, β 2 microglobulin and the like.
【0022】使用方法 中実繊維膜状多孔質支持体にリガンドを不溶化して得ら
れた吸着材は、そのまま或いは短く切断し、或いは綿状
にして、容器に充填してカラムとして使用できる。或い
は織布、不織布状に加工した上記吸着材を、例えば該織
布や不織布を重ねて平板状にしたり円筒状に巻いて容器
に充填して、カラムとして使用できる。或いは中実繊維
膜状多孔質支持体にリガンドを不溶化して得られた吸着
材の一部を接着剤等で容器に固定して使用することもで
きる。更に2種以上の吸着材が層状に、或いはランダム
に共存していても良い。容器は吸着処理される溶液の流
入口と流出口とを有し、吸着材が実質的に流出しない構
造で有れば良い。この時、容器の総内容積に対する吸着
材容積の割合は20%以上90%以下の物が好ましく、
より好ましい範囲をあえてあげると40%以上80%以
下が特に優れている。実際の使用に当たっては血液を直
接灌流しても良いし、あらかじめ遠心分離法或いは膜法
等によって分離して得た血漿を灌流しても良い。この時
血液または血漿は連続的に灌流しても、或いは断続的に
灌流しても良い。特に、本発明の繊維状多孔質支持体に
リガンドを不溶化して得られた吸着材は、繊維を束状に
して該束の両端をウレタンやシリコン接着剤等を用いて
束形状を保ち、該容器に固定されている時、血小板の通
過性に優れており、血液を直接灌流する目的に好ましく
使用できる。この時、束の容器への固定は該接着剤によ
って成されていても良く、また容器構造を利用した物理
的な方法によって固定されていても良い。Method of Use The adsorbent obtained by insolubilizing the solid fiber membrane-like porous support with the ligand can be used as it is, or cut into short pieces, or made into cotton and packed in a container to be used as a column. Alternatively, the adsorbent that has been processed into a woven or non-woven fabric can be used as a column by, for example, stacking the woven or non-woven fabric into a flat plate or rolling it into a cylinder and filling the container. Alternatively, a part of the adsorbent obtained by insolubilizing the ligand on the solid fiber membrane porous support may be fixed to the container with an adhesive or the like before use. Further, two or more kinds of adsorbents may coexist in layers or randomly. The container may have an inflow port and an outflow port for the solution to be adsorbed, and may have a structure in which the adsorbent does not substantially flow out. At this time, the ratio of the adsorbent volume to the total internal volume of the container is preferably 20% or more and 90% or less,
Taking a more preferable range, 40% or more and 80% or less is particularly excellent. In actual use, blood may be directly perfused, or plasma obtained by previously separating by a centrifugation method or a membrane method may be perfused. At this time, blood or plasma may be continuously perfused or intermittently perfused. In particular, the adsorbent obtained by insolubilizing the ligand on the fibrous porous support of the present invention is a bundle of fibers and both ends of the bundle are kept in a bundle shape by using urethane or silicone adhesive, When it is fixed in a container, it has excellent platelet passage properties and can be preferably used for the purpose of directly perfusing blood. At this time, the bundle may be fixed to the container by the adhesive, or may be fixed by a physical method using the container structure.
【0023】[0023]
【発明の効果】本発明の中実繊維膜状多孔質支持体は、
有効表面積が増大されているので、表面に多くのリガン
ドを容易に且つ安定に固定でき、しかも湿潤状態で安定
であり、汎用性のある吸着材用支持体として優れてい
る。The solid fiber membrane-like porous support of the present invention comprises:
Since the effective surface area is increased, many ligands can be easily and stably fixed on the surface, and moreover, it is stable in a wet state, and it is excellent as a versatile adsorbent support.
【0024】[0024]
【実施例1】高密度ポリエチレン(密度0.968、M
I値5.5、商品名ハイゼックス2208J)を紡口径
35mmの円形紡口を用いて、紡口温度150℃、ポリ
エチレン吐出量16g/分、紡糸距離5m、紡糸冷却温
度20℃、巻き取り張力10gf、巻き取り速度400
m/分、で溶融紡糸した。この時のドラフト比は24,
000であった。紡糸後115℃で2時間アニール処理
した。得られたポリエチレン糸を室温(22℃)にて、
1次ローラー速度3.75m/分、2次ローラー速度5
m/分で冷延伸した。この時の冷延伸倍率は約1.3倍
であった。次に連続して108℃、119℃、122℃
の3段階の温度で、それぞれのローラー速度15m/
分、19.5m/分、21.8m/分の延伸速度で熱延
伸して延伸開孔し、中実繊維膜状多孔質構造のポリエチ
レン製の多孔質支持体を得た。多孔質支持体の総延伸倍
率は5.8倍、糸径176μm、巻き取り長15kmで
あった。多孔質支持体をは水銀圧入法による平均孔径
0.20μm、全細孔容積3.6ml/g、空孔率7
7.8%、全表面積71.03m2 /g、孔径0.01
μm以上10μm以下の細孔の容積は全細孔容積の84
%であった。多孔質支持体(長さ12cm、1,000
本)に窒素雰囲気下で200kGyの電子線を照射し
た。照射後直ちに10%のグリシジルメタクリレートを
溶解したメタノール溶液に浸漬し、40℃、10分間反
応させた。重量変化より求めたグラフト率は98.2%
であり、大量のエポキシ基を導入できた。このエポキシ
基導入多孔質支持体に10%ジエチルアミンを溶解した
pH10.0の水溶液中で、ジエチルアミンを反応させ
て、ジエチルアミノ基を表面に有する吸着材を得た。こ
の吸着時の総イオン交換容量は1g当たり1.8ミリ当
量であった。。次に吸着材700本(充填率35%)
を、内径8mm、長さ10cmのポリカーボネート製の
円筒形の容器に、容器の長さ方向に吸着材を並べて挿入
し、吸着材両端部を容器と共にウレタンで接着固定し
た。この時容器両端はウレタンで密閉された。容器には
別に側面に入口と出口を設けておいた。入口と出口は両
端のウレタンでふさがれず、且つお互いに最も離れた位
置に設けた。以上のようにして吸着器を得た。得られた
吸着器に、0.3%の牛アルブミンを含む生理食塩液に
ビリルビン20mg/dlの濃度に溶解した液16ml
を、0.2ml/分で灌流し、吸着器流出液中のビリル
ビン濃度を測定してビリルビン吸着率を求めた。この時
の吸着率は64%であり、非常に優れた吸着性を示し
た。次に得られた吸着器を用いて血液の直接灌流性につ
いて評価した。抗凝固剤としてACD−A1/9容の存
在下で健常人血液を採取した。この血液40mlを吸着
器に1.2ml/分で灌流し、吸着器流出液中の血小板
数を測定したところ、血小板の減少率は12.3%と僅
かであった。Example 1 High-density polyethylene (density 0.968, M
I value of 5.5, trade name Hi-Zex 2208J) using a circular spinneret with a spinneret diameter of 35 mm, spinning temperature 150 ° C., polyethylene discharge rate 16 g / min, spinning distance 5 m, spinning cooling temperature 20 ° C., winding tension 10 gf , Winding speed 400
Melt spinning was performed at m / min. The draft ratio at this time is 24,
It was 000. After spinning, it was annealed at 115 ° C. for 2 hours. The obtained polyethylene yarn at room temperature (22 ° C),
Primary roller speed 3.75 m / min, secondary roller speed 5
Cold drawing was performed at m / min. The cold draw ratio at this time was about 1.3 times. Next 108 ° C, 119 ° C, 122 ° C continuously
Roller speed of 15m /
Min., 19.5 m / min, and 21.8 m / min, and drawn at a drawing speed to draw holes to obtain a polyethylene porous support having a solid fiber membrane-like porous structure. The total draw ratio of the porous support was 5.8 times, the yarn diameter was 176 μm, and the winding length was 15 km. The porous support has a mean pore size of 0.20 μm, a total pore volume of 3.6 ml / g, and a porosity of 7 according to the mercury porosimetry.
7.8%, total surface area 71.03 m 2 / g, pore size 0.01
The volume of pores having a size of μm to 10 μm is 84 of the total pore volume.
%Met. Porous support (length 12 cm, 1,000
Electron beam of 200 kGy in a nitrogen atmosphere. Immediately after the irradiation, it was immersed in a methanol solution in which 10% glycidyl methacrylate was dissolved and reacted at 40 ° C. for 10 minutes. Graft ratio calculated from weight change is 98.2%
Therefore, a large amount of epoxy groups could be introduced. Diethylamine was reacted in an aqueous solution of 10% diethylamine dissolved in this epoxy group-introduced porous support at pH 10.0 to obtain an adsorbent having a diethylamino group on the surface. The total ion exchange capacity at the time of adsorption was 1.8 meq / g. . Next, 700 adsorbents (filling rate 35%)
The adsorbent was inserted side by side in the lengthwise direction of the container into a cylindrical container made of polycarbonate having an inner diameter of 8 mm and a length of 10 cm, and both ends of the adsorbent were bonded and fixed together with the container by urethane. At this time, both ends of the container were sealed with urethane. The container had separate inlets and outlets on the side. The inlet and outlet were not blocked by urethane at both ends, and were provided at positions farthest from each other. The adsorber was obtained as described above. 16 ml of a solution prepared by dissolving bilirubin in a physiological saline solution containing 0.3% bovine albumin at a concentration of 20 mg / dl was added to the obtained adsorber.
Was perfused at 0.2 ml / min and the bilirubin concentration in the effluent of the adsorber was measured to determine the bilirubin adsorption rate. The adsorption rate at this time was 64%, which was a very excellent adsorption property. Then, the obtained adsorber was used to evaluate the direct perfusion of blood. Normal human blood was collected in the presence of ACD-A1 / 9 as an anticoagulant. When 40 ml of this blood was perfused into the adsorber at 1.2 ml / min and the number of platelets in the adsorber effluent was measured, the reduction rate of platelets was as small as 12.3%.
【0025】[0025]
【実施例2】実施例1において、紡糸時のポリエチレン
吐出量8g/分、巻き取り張力8.4gf、巻き取り速
度500m/分、熱延伸時の温度条件を98℃、104
℃、119℃として中実繊維膜状多孔質構造のポリエチ
レン製の多孔質支持体を得た(総延伸倍率5.8倍、糸
径112μm、巻き取り長15km)。多孔質支持体
は、水銀圧入法による平均孔径0.11μm、全細孔容
積2.7ml/g、全表面積102.3m2 /g、孔径
0.01μm以上10μm以下の細孔の容積は全細孔容
積の92%であった。多孔質支持体(長さ10cm、1
00本)を10%のグリシジルメタクリレートを溶解し
たメタノール溶液に浸漬し、窒素雰囲気下で25kGy
のγ線を照射した。重量変化より求めたグラフト率は
8.3%であった。このエポキシ基導入多孔質支持体に
0.1N水酸化ナトリウム水溶液中でフェニルアラニン
を反応させて、表面にフェニルアラニンを有する吸着材
を得た。フェニルアラニンの固定量は吸着材1ml当た
り53μ当量であった。この吸着材100本を1mlの
シリンジに充填し、慢性関節リウマチ患者血漿1mlを
0.01ml/分で灌流した。灌流前の血漿中の免疫複
合体の濃度が25.3μg/mlであったのに対して灌
流後の免疫複合体の濃度は10.0μg/ml以下であ
り、吸着による免疫複合体の減少率60.0%以上の優
れた免疫複合体の吸着能力を示した。[Example 2] In Example 1, the amount of polyethylene discharged during spinning was 8 g / min, the winding tension was 8.4 gf, the winding speed was 500 m / min, and the temperature conditions during hot drawing were 98 ° C and 104 ° C.
At 119 ° C., a polyethylene porous support having a solid fiber membrane porous structure was obtained (total draw ratio: 5.8 times, yarn diameter: 112 μm, winding length: 15 km). The porous support has an average pore diameter of 0.11 μm, a total pore volume of 2.7 ml / g, a total surface area of 102.3 m 2 / g, and a volume of pores of 0.01 μm or more and 10 μm or less, which are determined by mercury porosimetry. It was 92% of the pore volume. Porous support (length 10 cm, 1
100 pieces) was immersed in a methanol solution in which 10% glycidyl methacrylate was dissolved, and 25 kGy in a nitrogen atmosphere.
Was irradiated with γ-rays. The graft ratio obtained from the change in weight was 8.3%. This epoxy group-introduced porous support was reacted with phenylalanine in a 0.1N sodium hydroxide aqueous solution to obtain an adsorbent having phenylalanine on its surface. The fixed amount of phenylalanine was 53 μ equivalents per 1 ml of the adsorbent. 100 ml of this adsorbent was filled in a 1 ml syringe, and 1 ml of rheumatoid arthritis patient plasma was perfused at 0.01 ml / min. The concentration of the immune complex in plasma before perfusion was 25.3 μg / ml, whereas the concentration of the immune complex after perfusion was 10.0 μg / ml or less, and the reduction rate of the immune complex due to adsorption was It showed an excellent immune complex adsorption capacity of 60.0% or more.
【0026】[0026]
【実施例3】高密度ポリエチレン(密度0.968、M
I値5.5、商品名ハイゼックス2208J)を紡口径
10mmの円形紡口を用いて、紡口温度150℃、ポリ
エチレン吐出量8g/分、紡糸距離5m、紡糸冷却温度
23℃、巻き取り張力3gf、巻き取り速度260m/
分、で溶融紡糸した。この時のドラフト比は7,000
であった。紡糸後115℃で2時間アニール処理した。
得られたポリエチレン糸を室温(25℃)にて、1次ロ
ーラー速度1.5m/分、2次ローラー速度2m/分で
冷延伸した。この時の冷延伸倍率は約1.3倍であっ
た。次に連続して108℃、119℃、122℃の3段
階の温度で、それぞれのローラー速度6m/分、7.8
m/分、8.7m/分の延伸速度で熱延伸して延伸開孔
し、中実繊維膜状多孔質構造のポリエチレン製の多孔質
支持体を得た。多孔質支持体の総延伸倍率は5.8倍、
糸径162μm、巻き取り長15kmであった。多孔質
支持体をは水銀圧入法による平均孔径0.36μm、全
細孔容積4.8ml/g、空孔率83.0%、全表面積
37.3m2 /g、孔径0.01μm以上10μm以下
の細孔の容積は全細孔容積の81%であった。多孔質支
持体(長さ10cm、250本)を、ヒドロキシエチル
メタクリレートとジエチルアミノエチルメタクリレート
との1.1の共重合体(分子量およそ13,000)3
%を溶解した50%エタノール水溶液100ml中に浸
漬し、50kGyのγ線を照射し、放射線グラフトし
た。重量変化より求めたグラフト率は28.3%であっ
た。得られた吸着材を綿状にし、入口と出口を有し、且
つそれぞれに吸着材の漏れ防止用のメッシュを備えた内
容積1mlのポリカーボネート製容器に充填して吸着器
を得た。この吸着器に、ヘパリン2U/mlを含む健常
人血漿3mlを、流速0.02ml/分で灌流した。灌
流前の血漿中のプレアルブミン濃度が28.7mg/d
lであったのに対し、吸着器流出血漿中のプレアルブミ
ン濃度は1.4mg/dlであり、吸着によるプレアル
ブミンの減少率は95.1%と優れた吸着性を示した。Example 3 High density polyethylene (density 0.968, M
I value 5.5, trade name Hi-Zex 2208J) using a circular spinneret with a spinneret diameter of 10 mm, spinning temperature 150 ° C., polyethylene discharge rate 8 g / min, spinning distance 5 m, spinning cooling temperature 23 ° C., winding tension 3 gf , Winding speed 260m /
And melt-spun. The draft ratio at this time is 7,000
Met. After spinning, it was annealed at 115 ° C. for 2 hours.
The obtained polyethylene yarn was cold-drawn at room temperature (25 ° C.) at a primary roller speed of 1.5 m / min and a secondary roller speed of 2 m / min. The cold draw ratio at this time was about 1.3 times. Next, at three consecutive temperatures of 108 ° C., 119 ° C. and 122 ° C., roller speeds of 6 m / min and 7.8, respectively.
A polyethylene porous support having a solid fiber membrane-like porous structure was obtained by hot drawing at a drawing speed of m / min and 8.7 m / min for drawing and opening. The total draw ratio of the porous support is 5.8 times,
The yarn diameter was 162 μm and the winding length was 15 km. The porous support has an average pore diameter of 0.36 μm, a total pore volume of 4.8 ml / g, a porosity of 83.0%, a total surface area of 37.3 m 2 / g, and a pore diameter of 0.01 μm or more and 10 μm or less by a mercury intrusion method. The volume of the pores was 81% of the total volume of the pores. A porous support (length 10 cm, 250 pieces) was used as a copolymer of hydroxyethyl methacrylate and diethylaminoethyl methacrylate 1.1 of 1.1 (molecular weight of about 13,000) 3.
It was immersed in 100 ml of a 50% ethanol aqueous solution in which 100% was dissolved, irradiated with 50 kGy of γ-rays, and radiation-grafted. The graft ratio obtained from the weight change was 28.3%. The adsorbent thus obtained was made into a cotton shape and filled in a polycarbonate container having an inlet and an outlet and each having a mesh for preventing leakage of the adsorbent and having an internal volume of 1 ml to obtain an adsorber. The adsorber was perfused with 3 ml of healthy human plasma containing 2 U / ml of heparin at a flow rate of 0.02 ml / min. Prealbumin concentration in plasma before perfusion was 28.7 mg / d
While the prealbumin concentration in the plasma discharged from the adsorber was 1.4 mg / dl, the prealbumin reduction rate due to adsorption was 95.1%, which was excellent.
Claims (2)
下の細孔を有し、全表面積3m2 /g以上500m2 /
g以下、孔径0.01μm以上10μm以下の細孔の容
積が全細孔容積の40%以上を有する有機高分子材料か
らなる中実繊維膜状多孔質支持体。1. Pore having an average pore diameter of 0.01 μm or more and 10 μm or less, and a total surface area of 3 m 2 / g or more and 500 m 2 /
A solid fibrous membrane-like porous support made of an organic polymer material having a volume of g or less and a pore diameter of 0.01 μm or more and 10 μm or less of 40% or more of the total pore volume.
下の細孔を有し、全表面積3m2 /g以上500m2 /
g以下、孔径0.01μm以上10μm以下の細孔の容
積が全細孔容積の40%以上を有する有機高分子材料か
らなる中実繊維膜状多孔質支持体の表面上に、リガンド
を不溶化してなる吸着材。2. Pore having an average pore diameter of 0.01 μm or more and 10 μm or less and a total surface area of 3 m 2 / g or more and 500 m 2 /
The ligand is insolubilized on the surface of a solid fiber membrane porous support made of an organic polymer material having a volume of pores of g or less and a pore diameter of 0.01 μm or more and 10 μm or less of 40% or more of the total pore volume. An adsorbent made of.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5114270A JPH06296860A (en) | 1993-04-19 | 1993-04-19 | Porous support and adsorption material |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP5114270A JPH06296860A (en) | 1993-04-19 | 1993-04-19 | Porous support and adsorption material |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH06296860A true JPH06296860A (en) | 1994-10-25 |
Family
ID=14633614
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP5114270A Pending JPH06296860A (en) | 1993-04-19 | 1993-04-19 | Porous support and adsorption material |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH06296860A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1291080A3 (en) * | 2001-09-10 | 2004-05-19 | Tosoh Corporation | Process for production of partially hydrophilized porous adsorbents |
| JP2004283604A (en) * | 1998-05-22 | 2004-10-14 | M Rigdon Lentz | Method and composition for cancer therapy |
| JP2005211887A (en) * | 2004-02-02 | 2005-08-11 | Canon Inc | Method for separating substances from liquids |
| JP2009095788A (en) * | 2007-10-18 | 2009-05-07 | Fujifilm Corp | Hazardous substance removal material and hazardous substance removal method |
| KR20170076665A (en) * | 2014-10-28 | 2017-07-04 | 도레이 카부시키가이샤 | Porous fibers, adsorbent material, and purification column |
| JP2017185221A (en) * | 2016-03-30 | 2017-10-12 | 東レ株式会社 | Adsorption column |
| WO2017188110A1 (en) * | 2016-04-27 | 2017-11-02 | 東レ株式会社 | Porous fiber, absorbing material, and purifying column |
| JP2020157293A (en) * | 2019-03-19 | 2020-10-01 | 東レ株式会社 | Porous fiber, adsorbent material and purification column |
-
1993
- 1993-04-19 JP JP5114270A patent/JPH06296860A/en active Pending
Cited By (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004283604A (en) * | 1998-05-22 | 2004-10-14 | M Rigdon Lentz | Method and composition for cancer therapy |
| EP1291080A3 (en) * | 2001-09-10 | 2004-05-19 | Tosoh Corporation | Process for production of partially hydrophilized porous adsorbents |
| JP2005211887A (en) * | 2004-02-02 | 2005-08-11 | Canon Inc | Method for separating substances from liquids |
| JP2009095788A (en) * | 2007-10-18 | 2009-05-07 | Fujifilm Corp | Hazardous substance removal material and hazardous substance removal method |
| RU2698881C2 (en) * | 2014-10-28 | 2019-08-30 | Торэй Индастриз, Инк. | Porous fibers, adsorbing material and purification column |
| JP2020090766A (en) * | 2014-10-28 | 2020-06-11 | 東レ株式会社 | Porous fiber, adsorption material and cleaning column |
| CN107075740A (en) * | 2014-10-28 | 2017-08-18 | 东丽株式会社 | Porous fibre, sorbing material and decontaminating column |
| EP3738668A1 (en) * | 2014-10-28 | 2020-11-18 | Toray Industries, Inc. | Porous fibers, adsorbent material, and purification column |
| JPWO2016067967A1 (en) * | 2014-10-28 | 2017-08-03 | 東レ株式会社 | Porous fiber, adsorbent material and purification column |
| EP3214210A4 (en) * | 2014-10-28 | 2018-06-13 | Toray Industries, Inc. | Porous fibers, adsorbent material, and purification column |
| KR20170076665A (en) * | 2014-10-28 | 2017-07-04 | 도레이 카부시키가이샤 | Porous fibers, adsorbent material, and purification column |
| US10265678B2 (en) * | 2014-10-28 | 2019-04-23 | Toray Industries, Inc. | Porous fibers, adsorbent material, and purification column |
| TWI649122B (en) * | 2014-10-28 | 2019-02-01 | 日商東麗股份有限公司 | Porous fibers, adsorbent materials, and purification columns |
| JP2017185221A (en) * | 2016-03-30 | 2017-10-12 | 東レ株式会社 | Adsorption column |
| JPWO2017188110A1 (en) * | 2016-04-27 | 2019-03-07 | 東レ株式会社 | Porous fiber, adsorbent material and purification column |
| KR20180137483A (en) * | 2016-04-27 | 2018-12-27 | 도레이 카부시키가이샤 | Porous fiber, adsorbent material and purification column |
| CN109072488A (en) * | 2016-04-27 | 2018-12-21 | 东丽株式会社 | Porous fiber, adsorbent material and purification column |
| RU2715533C1 (en) * | 2016-04-27 | 2020-02-28 | Торэй Индастриз, Инк. | Porous fibre, adsorbing material and cleaning column |
| WO2017188110A1 (en) * | 2016-04-27 | 2017-11-02 | 東レ株式会社 | Porous fiber, absorbing material, and purifying column |
| TWI724159B (en) * | 2016-04-27 | 2021-04-11 | 日商東麗股份有限公司 | Porous fiber, adsorption material and purification column |
| US11596922B2 (en) | 2016-04-27 | 2023-03-07 | Toray Industries. Inc. | Porous fiber, adsorbent material, and purification column |
| JP2020157293A (en) * | 2019-03-19 | 2020-10-01 | 東レ株式会社 | Porous fiber, adsorbent material and purification column |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5286449A (en) | Adsorber module for whole blood treatment and an adsorber apparatus containing the adsorber module | |
| CA2603073C (en) | Absorbent and column for extracorporeal circulation | |
| EP0341413B2 (en) | An adsorber module and adsorber apparatus for whole blood treatment | |
| JP6922006B2 (en) | How to purify biomolecules in a sample | |
| US5498336A (en) | Leukocyte-removing filter and leukocyte-removing apparatus furnished therewith | |
| US20100176051A1 (en) | Adsorption carrier containing composite fiber | |
| CN117062660A (en) | filter media | |
| CN113677429B (en) | Adsorption material of soluble tumor necrosis factor receptor | |
| CN114423470A (en) | Blood treatment material | |
| JPH06296860A (en) | Porous support and adsorption material | |
| CN101267850B (en) | Method of removing white blood cells from blood | |
| JP5167727B2 (en) | Adsorption carrier containing composite fiber | |
| JP5784008B2 (en) | Ligand immobilization substrate and method for producing the same | |
| JP3353945B2 (en) | Coated carrier | |
| JP2814399B2 (en) | Adsorber for whole blood processing | |
| WO2013047527A1 (en) | Substrate for ligand immobilization and method for producing same, specific cell separation agent, and blood treatment unit | |
| JP4997770B2 (en) | Adsorber | |
| JP5017996B2 (en) | Leukocyte and cytokine adsorber | |
| JP2002172163A (en) | Cell adsorbent material and column for extracorporeal circulation and method for manufacturing them | |
| JPH0260660A (en) | Adsorbent for treating body fluid | |
| JP4982100B2 (en) | Adsorption carrier and extracorporeal circulation column | |
| JP2002212333A (en) | Antithrombotic porous membrane and method for producing the same | |
| JPS61253071A (en) | Blood purifying apparatus | |
| JPH0133228B2 (en) | ||
| JP2025036356A (en) | Biocomponent Adsorption Materials |